EUVIMEDEUVIMED entdecken
Validierungsstudie

Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation

Patrick Lewicki iD, Ralph Jiang, Archana Radhakrishnan, Alex Bryant, Matthew Schipper, Todd M Morgan, Kristian Stensland iD

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-25-02036 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Patrick Lewicki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Michigan, Ann Arbor, Michigan (P.L., T.M.M.). Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Early Detection of Cancer. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer (PCa) screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy. OBJECTIVE: To develop, externally validate, and compare to existing tools a novel prognostic model for risk for prostate cancer-specific mortality (PCSM) after a PSA test. DESIGN: Prognostic model development in the PCa screening group of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial; external validation in a Veterans Affairs (VA) population of patients undergoing PSA testing. SETTING: United States. PLCO patients were enrolled from 1993 to 2001, and VA patients underwent PSA testing from 2002 to 2006. Survival follow-up was updated through 2022 in both cohorts. PATIENTS: Male patients aged 55 to 74 years in the PLCO PCa screening group (n = 33 339) and the VA Healthcare System (n = 174 787). MEASUREMENTS: The model's predicted outcome is PCSM at a specified time point; predictors included PSA level, family history of PCa, and race. Predictors of other-cause mortality included age; body mass index; smoking status; and presence of hypertension, diabetes, or stroke. RESULTS: In the model development cohort, the area under the receiver operating characteristic curve (AUC) at 29.5 years from screening was 0.666 compared with 0.643 for a previously validated prostate biopsy risk model (Prostate Biopsy Collaborative Group [PBCG]) (P < 0.001). In the external validation cohort, the AUC at 20 years from screening was 0.776 for the PLCO model versus 0.749 for the PBCG model (P = 0.031). LIMITATION: The model may not be generalizable to more contemporary PSA screening practices given the periods studied. CONCLUSION: This PCSM prognostic model was developed from long-term clinical trial data, was externally validated in a large national cohort, and may be used to improve interpretation of PSA results. PRIMARY FUNDING SOURCE: None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsEarly Detection of CancerHumansMalePrognosisMiddle AgedAgedRisk AssessmentUnited StatesRisk Factors

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University of Michigan, Ann Arbor, Michigan (P.L., T.M.M.).
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan (R.J.).
  • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (A.R.).
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan (A.B.).
  • Department of Biostatistics and Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan (M.S.).
  • Department of Urology and Department of Learning Health Sciences, University of Michigan, Ann Arbor, Michigan (K.S.).

ORCID-Profile: Patrick Lewicki, Kristian Stensland

Zitieren

APA

Lewicki, P., Jiang, R., Radhakrishnan, A., Bryant, A., Schipper, M., Morgan, T. M., & Stensland, K. (2026). Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-02036

Vancouver

Lewicki P, Jiang R, Radhakrishnan A, Bryant A, Schipper M, Morgan TM, et al. Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-02036

BibTeX
@article{Lewicki2026,
  author = {Lewicki, Patrick and Jiang, Ralph and Radhakrishnan, Archana and Bryant, Alex and Schipper, Matthew and Morgan, Todd M and Stensland, Kristian},
  title = {Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-25-02036}
}
Kostenlos starten →